On March 17, 2022 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that management will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results and provide an operational update on Monday, March 21, 2022, at 5:00 p.m. ET (Press release, ORIC Pharmaceuticals, MAR 17, 2022, View Source [SID1234610270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast and Conference Call

To participate in the conference call, please dial (833) 651-0991 (domestic) or (918) 922-6080 (international) and refer to conference ID 8637367. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

On March 17, 2022 Nanjing Bioheng Biotech Co., Ltd reported that China National Drug Administration Drug Review Center (CDE) approved first Universal Chemeric Antigen Receptor T (UCAR-T) cell drug (Acceptance No. : CXSL2101509). CTA101 is independently developed by targeting CD19 and CD22, for the indication of adult recurrent or refractory B-cell acute lymphoblastic leukemia ( r / r B-ALL ) (Press release, Bioheng Biotech, MAR 17, 2022, View Source;301505078.html [SID1234610288]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The approval of CTA101 product IND is an important milestone for Bioheng in developing innovative immuno-cell therapies", said Xiaohong He, CEO of Bioheng."It will further accelerate the development and commercialization of "off-the-shelf" allogeneic CAR-T, which potentially offers greater benefits to patients over autologous CAR-T. We look forward to pushing more such disruptive products to clinical and providing more choices to solve the unmet medical needs and treatment accessibility".

On March 17, 2022 PokeAcell reported that it has initiated clinical testing of poke-101 in Melanoma in collaboration with National Center for Cancer Immune Therapy at Herlev Hospital and DTU Health Tech (Press release, PokeAcell, MAR 17, 2022, View Source [SID1234610218]). The trial will evaluate the safety and feasibility of treatment with PokeAcells ImmPACT cell product in Metastatic Melanoma and the first patients have received infusion in Q1 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PokeAcells’ personalized cell product is produced for each individual patient and this trial offer a unique insight to the feasibility of patient specific manufacturing with the ImmPACT technology and safety of the treatment. Poke-101 is a multi-targeted T cell product made from T cells in patients own blood. The T cells are stimulated against a library of 30 shared melanoma antigens with PokeAcells proprietary ImmPACT technology.

On March 17, 2022 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, reported that preclinical data supporting the ongoing development of its conditionally activated cytokine program will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting on April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Press release, CytomX Therapeutics, MAR 17, 2022, View Source [SID1234610255]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Type I interferons, as monotherapy or in combination with PD-(L)1 blockade, are powerful antitumor agents, but the toxicity of these therapies, including interferon alpha, can limit their clinical use. We are working to address this limitation with our conditionally activated cytokine program," said Marcia P. Belvin, Ph.D., senior vice president and head of research at CytomX Therapeutics. "At the upcoming AACR (Free AACR Whitepaper) Annual Meeting, we will report encouraging preclinical data that support the development of our conditionally activated interferon alpha-2b therapeutic candidate as a promising addition to current immunotherapy regimens, potentially expanding benefit to patients with typically unresponsive tumors. This program represents the leading edge of a broad initiative at CytomX towards enhancing the therapeutic window of multiple cytokines."

Details for the poster presentation are as follows:
Presentation Title: Probody-interferon-alpha 2b combines antitumor activity with improved tolerability
Abstract Number: 2071
Session Title: Immunomodulatory Agents and Interventions 1
Session Date and Time: Monday, April 11, 2022, 1:30 – 5:00 pm CT

On March 17, 2022 Manhattan Scientifics Inc. (OTCQB: MHTX ), reported that positive early results from Imagion Biosystems Cancer Diagnostic human study (Press release, Manhattan Scientifics, MAR 17, 2022, View Source [SID1234610289]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Imagion Biosystems Ltd. (IBX.AX) shares were up 46% trading 71 million shares.

Manhattan Scientifics Inc., initially funded and is the current owner of more that 50 million shares of Imagion Biosystems Ltd.